Susan A. Knudson
2021 - Conatus Pharmaceuticals
In 2021, Susan A. Knudson earned a total compensation of $539.2K as Executive Vice President, Chief Operations Officer & Chief Financial Officer at Conatus Pharmaceuticals, a 14% decrease compared to previous year.
Compensation breakdown
| Option Awards | $108,640 |
|---|---|
| Salary | $385,246 |
| Stock Awards | $45,267 |
| Total | $539,153 |
Knudson received $385.2K in salary, accounting for 71% of the total pay in 2021.
Knudson also received $108.6K in option awards and $45.3K in stock awards.
Rankings
In 2021, Susan A. Knudson's compensation ranked 10,563rd out of 12,415 executives tracked by ExecPay. In other words, Knudson earned more than 14.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,563 out of 12,415 | 15th |
Division Manufacturing | 4,669 out of 5,505 | 15th |
Major group Chemicals And Allied Products | 2,099 out of 2,375 | 12th |
Industry group Drugs | 1,863 out of 2,096 | 11th |
Industry Pharmaceutical Preparations | 1,381 out of 1,546 | 11th |
Source: SEC filing on May 1, 2023.
Knudson's colleagues
We found one more compensation record of an executive who worked with Susan A. Knudson at Conatus Pharmaceuticals in 2021.
2021
Steven Mento
Conatus Pharmaceuticals
Chief Executive Officer
News
Conatus Pharmaceuticals CFO Susan Knudson's 2022 pay jumps 26% to $681K
May 1, 2023
Conatus Pharmaceuticals CEO Steven Mento's 2020 pay slips 5% to $1.3M
April 15, 2021
Pfenex CEO Evert Schimmelpennink's 2019 pay rises 11% to $1.8M
April 1, 2020
Neothetics CEO Saundra Pelletier's 2018 pay jumps 401% to $8.3M
April 24, 2019
Pfenex CEO Evert Schimmelpennink's 2018 pay jumps 47% to $1.6M
April 4, 2019